Trends & Forecasts

EFPIA figures give a snapshot of drug development and innovation in Europe. Check out our infographic for some of the key stats.

No-deal Brexit poses unique challenges for the development and advanced therapy sectors, not least tight timelines and a limited ability to stockpile.

Gene therapy deals, clinical trials transparency and sartan medicine reviews… what’s new for pharma in business?

With the US back to divided government, the US pharma industry could be the number one target for politicians.

Conversations around drug pricing look set to continue for years, but the industry is also experiencing fantastic breakthroughs in science.

As ever, our industry will have to deal with its fair share of sociopolitical “fun” in 2019. But what can we do?

2019 Power List nominations close in just one month. Who’s in the running? Well, that’s up to you…

Cell and gene therapies can live up to their potential – the field just needs to transform medicine as we know it.

The pharma industry understands the importance of neglected diseases, but the field is still not receiving the attention it deserves.

Brexit: As UK politicians debate the merits of the Prime Minister’s Withdrawal Agreement, we debate its potential impact for pharma...